PMDD: Severe Premenstrual Neuropsychiatric Syndrome
Premenstrual dysphoric disorder (PMDD) affects approximately 5–8% of menstruating women, causing severe mood symptoms—depression, anxiety, irritability—in the luteal phase of the menstrual cycle. PMDD results from abnormal sensitivity to normal hormone fluctuations, particularly progesterone and its metabolite allopregnanolone.
PFAS and Progesterone Pathway Disruption
PFAS compounds disrupt progesterone synthesis and metabolism, altering luteal phase hormone profiles. PFAS also affect GABA-A receptor sensitivity to allopregnanolone—the neurosteroid whose central effects are abnormally processed in PMDD. PFAS-induced GABA-A receptor alterations may amplify the neurological hypersensitivity to hormonal fluctuations characteristic of PMDD.
Mood and Inflammatory Pathways
PFAS-induced neuroinflammation elevates brain inflammatory cytokines that worsen mood vulnerability during hormonal transitions. Elevated brain TNF-alpha and IL-1β—promoted by PFAS exposure—increase sensitivity to depressive mood states, potentially exacerbating PMDD symptom severity in PFAS-exposed women.
Reproductive Psychiatry Considerations
Psychiatrists and OB/GYNs managing PMDD should consider environmental exposure assessment in patients with severe or treatment-resistant presentations. PFAS body burden evaluation and exposure reduction strategies may complement standard PMDD treatments including SSRIs, hormonal therapies, and cognitive behavioral approaches